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Tuberculosis remains a major health problem due to the emergence of drug-resistant strains ofMycobacterium tuberculosis.
Somemodels have provided valuable information about drug resistance and efficacy; however, the translation of these results
into effective human treatments has mostly proven unsuccessful. In this study, we adapted high-content screening (HCS) tech-
nology to investigate the activities of antitubercular compounds in the context of an in vitro granuloma model. We observed
significant shifts in the MIC50s between the activities of the compounds under extracellular and granuloma conditions.
Tuberculosis (TB) is a respiratory disease that is one of the ma-jor causes of mortality and morbidity worldwide. Almost 20
people develop TB and four patients die from the disease every
minute somewhere in the world (1). The disease can be cured by
drug treatment involving a regimen of several drugs. The World
HealthOrganization (WHO) estimates that there were around 0.5
million new cases of multidrug-resistant TB (MDR-TB) in 2012
(2, 3). A recent report confirmed that MDR-TB is a continuing
worldwide health problem, even in high-income countries with a
low incidence of TB (4).
The immune system undoubtedly plays a major role in TB
control (5). Signaling events of the immune system lead to the
formation of a granuloma, the hallmark of TB. Granulomas are an
immune microenvironment in which the infection can be con-
trolled but also a niche in which bacilli can thrive and modulate
immune responses to ensure their survival for long periods with-
out causing damage (6, 7). Granulomas are cell aggregates that
form tridimensional and heterogeneous structures (8, 9).We pre-
viously described an in vitro granuloma model involving human
blood cells either infected with mycobacteria or incubated with
mycobacterial antigens (8, 10). Either of these models resulted in
the formation of a typical epithelioid granulomawithmorpholog-
ical characteristics and properties of cellular differentiation simi-
lar to those of natural granulomas (8, 10, 11). Thismodelmay help
bridge the gap between the in vitro evaluation of MICs and costly
in vivo efficacy studies in guinea pigs. In particular, compounds
that are effective in the in vitro granuloma model could be prior-
itized for guinea pig studies.
High-content screening (HCS) technology has been used to
identify anti-TB compounds (12–14). This technology has several
advantages over traditional phenotypic screening approaches.
This technology has mostly been used in single-cell experiments,
because it is adapted to identify and analyze images (12, 13); how-
ever, in this paper, we focus on the use of granulomas instead of
single cells. In this report, we describe the development of a novel
HCS method to evaluate the activities of reference compounds
against a green fluorescent protein (GFP)-expressing H37Rv
strain of Mycobacterium tuberculosis (MTB-GFP) within 5 days,
and we compared the MIC50 values with those of classical liquid
cultures (extracellular), intracellular growth (single-cell assay),
and within granulomas, all using the same bacterial strain.
MTB-GFP strains (13)were grown for 3weeks at 37°Cuntil the
log phasewas reached. The test inoculumwas prepared by diluting
the culture with phosphate-buffered saline (PBS) medium or
complete RPMI (RPMIc) medium (containing RPMI 1640 me-
dium supplementedwith 10%heat-inactivated fetal bovine serum
[FBS], with 1% glutamine, 1% HEPES, 1% nonessential amino
acids) to a final bacterial concentration of 1 106 CFU/ml.
In vitro human granuloma formation was performed by incu-
bating peripheral blood mononuclear cells (PBMC) of healthy
volunteers; the cells were purified by gradient density sedimenta-
tion (15) with MTB-GFP using an appropriate multiplicity of in-
fection in RPMIcmedium at 37°Cwith low shaking (125 rpm) for
1 h; they were then washed with PBS containing 2% FBS and
suspended in RPMIcmedium at a concentration of 3.5 105 cells
per well in 384-well plates (Greiner). The cells were then incu-
bated for 3 days at 37°C in a 5% CO2 atmosphere to allow the
formation of granulomas.
Intragranuloma bacterial quantification was performed by fix-
ing granulomaswith 4%paraformaldehyde (ElectronMicroscopy
Sciences) in PBS and staining with Hoechst (Sigma); each step
consisted of a 30-min incubation period at room temperature.
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The plates were sealedwith optical adhesive film (Excel Scientific),
and the images were recorded using CellInsight Thermo Array-
Scan HCS equipment (Thermo Fisher Scientific) with a 10 ob-
jective. A 386-nm laser with an exposure time of 4 ms was used to
analyze Hoechst staining, and a 485-nm laser with an exposure
time of 597.286 ms was used to analyze GFP fluorescence. Each
image was processed using Cellomics ArrayScan compartmental
analysis (version 3). For the acquisition of the entire 384-well mi-
crotiter plate, 16 fields within each well were recorded. All fields
contained two images, cell nuclei (blue channel) and bacteria
(green channel). The granuloma structures were selected accord-
ing to nuclei staining, due to the complexity of the size and formof
the cells. Tests were carried out to evaluate the different settings
used to identify granulomas, and the blue channel was finally cho-
sen for identifying the granulomas (Fig. 1B). Using this approach,
the granulomas could easily be distinguished from the PBMC and
single cells, and cell aggregates could be eliminated. Spot detection
was used to detect bacteria, because this approach can detect a
single bacterium and thus give the exact number of bacteria (Fig.
1C). This method was validated in experiments involving suspen-
sions of bacteria of known concentrations. Some variables gener-
ated from the granuloma protocol are the number of granulomas,
area, size, intensity, spot, and number of granulomas/spot.
A dose-response assay to determine the MICs was performed
by testing four drugs: isoniazid (INH), moxifloxacin (MOX), lin-
ezolid (LZD), and pyrazinamide (PZA). We used INH as a refer-
ence control because it is a potent mycobactericidal drug and a
vital component of current combination regimens. LZD was cho-
sen as an example of a compound that has recently shown great
promise in the clinical setting, despite poor performance in mu-
rine animal models of TB (16). PZA has poor in vitro anti-TB
activity when used alone but can boost other anti-TB drugs when
used in combination, both in animal models and in the clinic
setting. MOX is a promising potential candidate for future drug
regimens, given its advanced clinical development status. We did
not observe any toxic effects to cells with the concentrations of
drugs tested. Stock solutions were prepared in high-grade di-
methyl sulfoxide (DMSO) (Sigma) at a concentration of 200 mM
and diluted for the assay with RPMIc to an appropriate concen-
tration. The granulomas were exposed to compounds for 5 days
under the same conditions as those previously described in order
to evaluate their effect onMTB-GFP-colonized granulomas. After
exposure, intragranuloma bacterial quantification was done as
previously described. All experimental settings were kept constant
to ensure that the same parameters were used in all analyses. How-
ever, all settings were recalibrated with respect to the granuloma
control image for each sample. The ArrayScan Cellomics software
provides many experimental variables; however, we focused on
the number of granulomas, the total spot count (number of bac-
teria), and the number of spots per granuloma (M. tuberculosis
cells per granuloma). The control granulomas and drug-treated
granulomas were compared to evaluate whether the drug brought
about a reduction in the number of bacteria in the granuloma
(MTB/granuloma). The number of spots and the number of gran-
FIG 1 Typical granuloma images recorded by the automated CellInsight Thermo ArrayScan. Shown are the same image at 10 objective in one field (A), in the
blue channel, with selected granulomas in blue and isolated cells or aggregated cells in orange (B), in the green channel, with bacteria as green spots (C), and as
a composite image of the two channels (D).
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ulomas were used as internal controls. The effect of the drug was
calculated as the percentage of inhibition of infection (PII), as
follows: PII [1 (sampleMTB/granuloma/DMSOMTB/granuloma)]
100. The experiment was repeated six times for each concentra-
tion for each donor. The intragranulomaMIC50was defined as the
concentration of drug required to achieve a 50% inhibition of
bacillus growth after 5 days of drug exposure. The MIC50 was
determined from the dose-response curves. The data analysis was
carried out with the GraphPad Prism version 5.02 software.
In the assay, DMSO did not show any toxic effect for cells at its
highest concentration (0.05% [vol/vol]). The number of granulo-
mas was used in our assay as an internal control for compound
toxicity. We verified the lack of toxicity of DMSO at a concentra-
tion of 0.05% in granulomas by comparing the number of granu-
lomas obtained in the presence of DMSO and that obtained with
control samples (without the addition of any compound); no dif-
ferences were found in the number of granulomas. Reference
compounds, such as INH, containing the sameDMSO concentra-
tion were evaluated in parallel. We found that the number of
MTB-GFP inside the granulomas was unchanged after 5 days of
incubation of infected cells with any compound (as a control) or
withDMSO. The reduction in the number ofMTB-GFP inside the
granulomas treated with INH was thus due only to the effect of
the drug and not to any toxic effect of the DMSO contained in the
drug sample added to the cells (data not shown).
The GFP-based readout reflects the number of viable bacteria
in the sample after antibiotic treatment. We used INH as a refer-
ence drug against MTB-GFP as previously described for a single-
cell assay (12, 13).Dose-response curveswere calculatedwith con-
centrations ranging from 1 109 M to 1 104 M, which were
the same as those used for a previously reported single-cell assay
(12).We calculated the PII of various concentrations of INHplot-
ted as an INH dose-response curve (Fig. 2). Each point represents
the PBMC isolated from at least nine healthy donors, and the
standard deviation is shown. At a concentration of 109M, the PII
was 18% and was directly proportional to the INH concentration
until reaching a plateau of 60% at 105M. Thus, theMIC50 under
these experimental conditions was around 0.59  106 or 0.59
M (i.e., 0.081 g/ml) (Fig. 2A). This value is similar to that
calculated for INH in the single-cell assay, with an MIC50 of 0.57
M (i.e., 0.078 g/ml) (Fig. 2B). In addition, the single-cell assay
results have been demonstrated to show a good correlation be-
tween the fluorescence counts and CFU counts obtained for ref-
erence compounds (12, 13). However, HCS screening would
never replace the CFU determination method, which is currently
the only technique that enables the exact determination of intra-
cellular bacterial load, even though it gives a faster determination
of the ability of a given drug to kill bacteria and enables a faster
determination of the MIC of a drug.
The antimycobacterial activities of various compounds against
MTB-GFP were determined by calculating the PII for each exper-
imental concentration (ranging from 1 nM to 1mM) to assess the
sensitivities of the bacteria inside artificial granulomas. At low
compound concentrations, the mean of the PII was low as a result
of MTB-GFP replication (high number of bacilli in granulomas).
At higher concentrations, themean of the PII increased, due to the
diminished number of bacilli in the granulomas. An inhibition of
infection of 100% was not reached with any drug (Fig. 3). We
calculated the MIC50s of drugs from dose-response curves and
compared them to those of extracellular and intracellular (in iso-
lated macrophage cultures) bacterial growth assays, performed in
parallel. The extracellular and intracellularMIC50 values were ob-
tained as previously described by Remuiñán et al. (17) and Chris-
tophe et al. (13), respectively. Under normal assay conditions
(medium pH 7), the MIC50s of INH, MOX, LZD, and PZA
against intracellular (artificial granuloma) MTB-GFP were 0.081,
4.12, 1.65, and 5 g/ml, respectively (Fig. 3). The MIC50s of
INH, MOX, LZD, and PZA against extracellular MTB-GFP were
0.05, 0.33, 0.098, and5g/ml, respectively. TheMIC50s of INH,
MOX, LZD, and PZA to intracellular bacteria (in macrophages)
were 0.052, 0.27, 0.159, and5g/ml, respectively. Amodest but
still measurable activity of PZA under the artificial granuloma
conditions was observed. Previous reports found that PZA is de-
void of any significant anti-TB activity under extracellular growth
conditions at concentrations up to 2 mg/ml (18), although some
activity is observed when bacteria are grown at pH 5.5, with an
MIC50 between 62.5 and 125g/ml (19). Reports of the activity of
PZA in infected macrophages are conflicting; some studies found
that PZAwas completely inactive (20, 21), whereas another report
found that PZA had a modest effect at around 20 g/ml (22). For
MOX and LZD, our results showed a shift (10- to 15-fold) in the
MIC50s between the activities of the compounds under extracel-
lular and artificial granuloma conditions. The MTB-GFP resis-
tance in an artificial granuloma model can be explained by the
poor permeability associated with the complex cellular composi-
tion of the granuloma, which may prevent the compound from
FIG 2 Comparison of the effect of the reference drug isoniazid against MTB-GFP in our in vitro granuloma assay (A) and its effect in murine Raw 264.7
macrophage assays (B). These two assays yielded similar dose-response curves. The results (mean standard deviation [SD] correspond to 9 independent donors
for panel A and 4 independent experiments for panel B) were normalized according to DMSO and INH control values.
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reaching the mycobacteria (8, 9). In addition, it has been well-
known for decades that inside the granuloma, the bacteria change
their physiological characteristics (11) and especially their exter-
nal envelope; therefore, their susceptibility to a given drugmay be
completely different from that under extracellular conditions or
even within single cells. Indeed, without the lymphocyte environ-
ment present around infected macrophages within the granulo-
mas, themacrophage intracellular environment is different in sin-
gle-cell assays, and a different environment with the bacterial
physiology may obviously trigger different types of physiological
adaptation by the bacteria and thus a different susceptibility to the
same drug. These differences in the bacterial physiological state
and thus its variable drug susceptibility is one of the main reasons
why we found it very important to develop a model of granuloma
to evaluate the bacterial susceptibilities to given drugs, because it
would of course be far more relevant to the natural environment
of the bacilli within infected individuals, where they are located in
granulomas. Altogether, these factors represent many obstacles
for compounds to access bacteria and may thus render them less
susceptible to small-molecule inhibitors, as was previously en-
countered in assays with nonreplicating bacteria. In both in-
stances, this seems to indicate that our in vitro granuloma model
shows a close resemblance to the low clearance rate of bacteria
observed in the clinic setting. Indeed, in this setting, systemic ex-
posure to high concentrations of anti-TB agents is generally re-
quired for prolonged periods to generate only small CFU reduc-
tions in the lungs of infected patients during the prolonged phase
of anti-TB treatment (23, 24).
The main advantage of this technology is that the MIC can
quickly be determined for compounds effective against intracel-
lular bacilli, and these values show a good correlation with the
CFU counts obtained for reference compounds (12). We adapted
HCS to screen reference compounds that target mycobacteria in-
side artificial granulomas. We used FBS in our assay to avoid in-
terference with human immune factors, except for those pro-
duced by PBMC. Additionally, we removed the extracellular
nonphagocytosed bacilli by selecting only mature granulomas of
index 2 to 4, as described previously (25). This ensured that only
internalized bacteria were counted, such that the assay specifically
measured the effects of compounds on mycobacteria inside the
granuloma. The significant shifts in the MICs observed between
the activities of the compounds under extracellular and artificial
granuloma conditions highlight the important differences be-
tween traditional methods to assessMICs and the artificial in vitro
granuloma system. The assessment ofMICs in granulomas is con-
sistent with the clinical reality that high concentrations of antibi-
otic administered over long periods of time are required to gener-
ate significant reductions in the CFU burdens of infected patients.
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FIG 3 Dose-response curves for various anti-TB agents in artificial granuloma assay. The antimycobacterial effect of each agent was determined by calculating
the percentage of inhibition of infection. We obtained MIC50s of 1.65 g/ml for LZD (A), 101.2 g/ml for PZA (B), and 4.12 g/ml for MOX(C).
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